Effect of Percutaneous Electrical Acupoint Stimulation on the Improvement of Incidence of Adverse Respiratory Events
Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Jan 12, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a specific treatment called Transcutaneous Electrical Acupoint Stimulation (TEAS) on patients recovering from general anesthesia. The researchers want to see if applying gentle electrical stimulation to certain acupuncture points on the arm can help reduce breathing problems after patients are taken off the breathing tube (a process called extubation). The study will include about 236 participants who are adults over 18 years old and are having elective surgeries that require general anesthesia. Those with serious heart or lung issues, certain psychiatric disorders, or infections will not be eligible.
Participants in the trial will be randomly assigned to one of two groups: one will receive the TEAS treatment, while the other will get regular care without the stimulation. After being extubated, the TEAS group will have electrodes placed on their arms for 30 minutes to help improve their breathing recovery, while the control group will receive standard oxygen therapy. Throughout the observation period, the medical team will carefully monitor all patients to ensure their safety. If everything goes well, patients will be cleared for discharge back to their hospital ward.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1: Age \>18 years old.
- • 2: ASA I-III
- • 3: Patients undergoing elective general anesthesia surgery who are extubated upon arrival to the PACU
- Exclusion Criteria:
- • 1: Preoperative comorbidities include severe cardiovascular or respiratory diseases
- • 2: Serious reflux aspiration during the perioperative period
- • 3: Concurrent psychiatric disorders
- • 4: Local skin infections or nerve damage at the upper limb Taiyuan and Hegu acupoints
About Nanjing First Hospital, Nanjing Medical University
Nanjing First Hospital, affiliated with Nanjing Medical University, is a leading medical institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care and cutting-edge medical practices, the hospital serves as a key player in the development of new therapies and treatment protocols. Its collaborative environment fosters interdisciplinary research, enabling the integration of scientific inquiry with clinical application. Nanjing First Hospital is committed to improving health outcomes and contributing to the global medical community through rigorous trial design and execution, ensuring the highest standards of ethical practice and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
Patients applied
Trial Officials
xiaoliang wang
Study Director
The First Affiliated Hospital with Nanjing Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported